Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.85
+$0.11 · +6.32%
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Regular session
$1.85
+$0.11 · +6.32%
Regular session · ET · Market data may be delayed.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Day range
Current $1.85
52-week range
Current $1.85
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
56
Mixed
Risk
78
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Day range
Current $1.85
52-week range
Current $1.85
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 3.11M USD | 12.29M USD |
| Cost of goods sold | 240K USD | 352K USD | — | — | — |
| Gross profit | −240K USD | −352K USD | — | 3.11M USD | 12.29M USD |
| Research and development | 14.54M USD | 14.38M USD | 17.11M USD | 17.88M USD | 18.99M USD |
| Selling, general, and administrative | 11.77M USD | 10.22M USD | 11.77M USD | 13.87M USD | 14.7M USD |
| Operating expenses | 26.07M USD | 24.25M USD | 28.88M USD | 31.76M USD | 33.69M USD |
| Depreciation and amortization | 240K USD | 352K USD | 567K USD | 901K USD | 1.14M USD |
| Operating income | −26.31M USD | −24.6M USD | −28.88M USD | −28.64M USD | −21.4M USD |
| Net income | −25.97M USD | −24.13M USD | −17.41M USD | 8.03M USD | −28.46M USD |
Company facts updated Sep 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 30, 2025 | 1:18 | — | — |
Stock split | May 27, 2025 | 1:20 | — | — |
Stock split | Dec 4, 2024 | 1:37 | — | — |
Stock split | Mar 6, 2024 | 1:44 | — | — |
Stock split | Mar 27, 2020 | 1:14 | — | — |
Effective Dec 30, 2025
1:18
Effective May 27, 2025
1:20
Effective Dec 4, 2024
1:37
Effective Mar 6, 2024
1:44
Effective Mar 27, 2020
1:14
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
